November is Stomach Cancer Awareness Month. With your help, we can fund more research and revolutionize the way stomach cancer is treated forever-curing more people and saving more lives. Give today to accelerate groundbreaking cancer immunotherapy research for stomach cancer: https://bit.ly/44of8ML #StomachCancerAwarenessMonth #StomachCancer #CancerResearch #Immunotherapy

Could CAR T cell therapy show promise against deadly childhood brain cancer? Marking one of its "first successes against solid tumors," results published in Springer Nature's Nature showcase how CAR T cell therapy shrank children’s brain tumors, restored neurologic function, and for one participant in the Stanford University School of Medicine clinical trial, erased all detectable traces of a brain cancer usually considered incurable. Dive deeper into the findings of investigators, including CRI Lloyd J. Old STAR Dr. Robbie Majzner, and explore their impact: https://stan.md/3YKutWh #DIPG #CancerResearch #ClinicalTrial #CARTCell

Though still in early clinical trials, E-SYNC, a form of 'switchable' CAR T cell therapy that can be turned on and off to better target cancer and reduce side effects, could one day become the first CAR T cell therapy to treat glioblastoma, University of California, San Francisco describes. Discover how this therapy holds promise for treating glioblastoma and even HER2-positive breast cancer, in a new blog post featuring CRI Clinical Accelerator Investigator Dr. Jennifer Clarke, who is leading the E-SYNC trial: https://bit.ly/3Z3rj1a #Glioblastoma #GBM #CancerResearch #CARTCell

Thanks to researchers funded by the Cancer Research Institute, 9 million people globally are now eligible for immunotherapy. Discover how CRI is spreading hope to cancer patients everywhere, by exploring our Impact Report: https://bit.ly/4hiBiGT #CancerResearch #Immunotherapy

What began as a routine visit to his primary care physician escalated quickly, landing retired US Navy Commander John Ryan in emergency care, where a CT scan revealed a tumor in his left lung. The diagnosis was stage 4 adenocarcinoma non-small cell lung cancer, a life-threatening disease expected to affect almost 200,000 Americans in 2024. This Veterans Day, discover how an immunotherapy clinical trial saved John's life, and hear how CRI-funded researchers, including CRI Lloyd J. Old STAR and US Navy Reserves Medical Corps Captain Dr. Gavin Dunn at Massachusetts General Hospital, are committed to improving access to cutting-edge treatments and clinical trials. “Our veterans represent a group of people who have given much in service to our country,” expresses Dr. Dunn. “Making sure they have the right access to clinical trial programs is a way that, as a country, we can help repay that service.” Explore: https://bit.ly/3AA1oEO #VeteransDay #Immunotherapy #ClinicalTrial #CancerResearch

29 cancers are now treatable with immunotherapy, thanks to the work of the Cancer Research Institute. Discover how CRI is bringing the promise of immunotherapy to more patients, and explore our transformative impact: https://bit.ly/4hiBiGT #CancerResearch #Immunotherapy

“Blocking access to inhibitory metabolites is a completely new take on how we can reinvigorate the immune system,” emphasizes CRI Lloyd J. Old STAR Dr. Greg Delgoffe to UPMC Hillman Cancer Center. “We often think of exhausted T cells [as] being useless, but this study shows that we can actually get juice out of these cells by blocking negative effects of the tumor microenvironment.” Discover how researchers including Dr. Delgoffe are reinvigorating T cells by blocking a solute carrier called MCT11, thereby improving tumor control in mouse models of cancer, in a new Springer Nature Nature Immunology publication: https://lnkd.in/eY_5qUrg #TCells #Immunotherapy #CancerResearch

“The Cancer Research Institute has always been the place in the field where innovation lives,” emphasizes CRI Scientific Advisory Council Associate Director Dr. E. John Wherry of Penn Medicine, University of Pennsylvania Health System. Discover how CRI-funded scientists are leading the charge to fuel the next wave of immunotherapy treatments: https://bit.ly/4hiBiGT #Immunotherapy #CancerResearch #CancerResearcher

Congratulations to CRI Scientific Advisory Council member Dr. Carl June of Penn Medicine, University of Pennsylvania Health System, who has been named one of the 150 Most Influential People in Philadelphia, by Philadelphia magazine. "June’s history-making CAR T cell therapy research is expanding around the world, showing progress with even more cancers and autoimmune diseases," the list describes. Learn more about this acknowledgment: https://bit.ly/3otgktE #CARTCell #CancerResearch #Immunotherapy

"I was one of the first lung cancer patients to participate in a clinical trial with immunotherapy. Immediately, when I had my first infusion, I felt a difference," says CRI ImmunoAdvocate Barry. "Something positive was going to happen." Hear Barry's first-hand account of his immunotherapy journey, during the Cancer Research Institute's virtual Patient Immunotherapy Summit: https://bit.ly/3YEZ4FV #LungCancer #LungCancerSurvivor #CancerResearch #Immunotherapy